Chris Morrison, Riku Lähteenmäki
Index: 10.1038/nbt.3917
Full Text: HTML
The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.